Home › NDC Lookup › Ingredients › Desoximetasone › 45802-0495-35
🧴image loading
(from DailyMed)

Desoximetasone 2.5 mg/g Cream — NDC 45802-495-35 (Billing 45802-0495-35)

by Padagis Israel Pharmaceuticals Ltd · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of Desoximetasone 2.5 mg/g Cream from Padagis Israel Pharmaceuticals Ltd, marketed since Oct 2006 and currently FDA-listed; retail pharmacies pay about $0.3979 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 45802-0495-35
🏷️ FDA NDC (as labeled) 45802-495-35 billing pads the product segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.3979 NADAC Per package$5.97 / 15 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.7738/unit · Part D plans $0.7357/unit — full pricing hub ↓
Main listing for product 45802-495 · Also comes in: 60 g 45802-495-37
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 45802-495-35 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
45802 labeler · 495 product · 35 package
Package marketed since
Nov 16, 2006
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 4580249535 8
Medicaid fills, this package
306 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 45802-495-35
Product NDC 45802-495
11-digit billing NDC 45802049535
NCPDP billing unit GM — per gram (weight)
Application # ANDA076510
SPL Set ID 31967bff-f076-42a6-92ec-6bb0960e311b
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2006-10-24
Route TOPICAL
Dosage form CREAM
Substance DESOXIMETASONE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 007583
GCN 31181
HICL code 003309
Ingredient (HICL) Desoximetasone
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 84:06.08.00
AHFS class Corticosteroids (Skin, Mucous Membrane)
FDB label name DESOXIMETASONE 0.25% CREAM
FDB brand name Desoximetasone
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007583
  • GCN: 31181
  • HICL (First Databank): 003309
  • AHFS class code: 84:06.08.00
Why two NDCs? The FDA registers this code as 45802-495-35 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 45802-0495-35. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name DESOXIMETASONE 0.25% CREAM Ingredient Desoximetasone
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Creams, gels and ointments calm inflamed, itchy skin from conditions that respond to steroids. The spray is used for plaque psoriasis in adults 18 and ol...
  • You put a thin film on the affected skin, usually twice a day, and rub it in gently. Don't cover the spray area with a bandage unless your doctor tells you to. Keep it away from yo...
  • Stop when your skin is under control. The label doesn't recommend using the spray beyond 4 weeks. Avoid your face, armpits and groin, and don't use it on skin that has thinned.
  • The most common are dryness, irritation and itching where you apply it. Call your doctor if you notice vision changes, thinning skin, stretch marks, or signs of infection.
📖 Read our full Desoximetasone guide →

Supplement & herbal interactions

Some supplements/herbs that may interact with Desoximetasone — tap one for details:

Dimethylsulfoxide (dmso)Moderate Turpentine OilModerate AlchemillaMinor
🌿 Every supplement checked against Desoximetasone (3 interactions) — ranked by severity →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.398 $5.97 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.7738 $11.61 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.7357 $11.04 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Dec 2021 Jul 2022 Jan 2026 Sep 2026 $1.045 $0.385
▼ Down 50% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
45802-0495-35 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.3979 / g $5.97 2006-11-16 — Active
45802-0495-37 45802-495-37 1 TUBE in 1 CARTON / 60 g in 1 TUBE $0.3227 / g $19.36 2006-10-24 — Active

Per g, this pack runs about 23% above the cheapest pack (NDC 45802-0495-37, $0.3227 vs $0.3979 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 82% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of Desoximetasone 2.5 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
desoximetasone 2.5 mg/g 72578-0095-01 Viona 1 tube $0.369 AB Availability likely save 7%
desoximetasone 2.5 mg/g 45802-0496-14 Padagis 1 tube $0.369 AB Availability likely save 7%
Desoximetasone 2.5 mg/g 68180-0946-01 Lupin 1 tube $0.369 AB Availability likely save 7%
Desoximetasone 2.5 mg/g 00472-0479-15 Actavis 1 tube $0.369 AB Availability likely save 7%
Desoximetasone 2.5 mg/g 00472-0478-15 Actavis 1 tube $0.394 — Discontinued save 1%
Desoximetasone 2.5 mg/gthis 45802-0495-35 Padagis 1 tube $0.398 AB Availability likely —
Desoximetasone 2.5 mg/g 68180-0950-01 Lupin 1 tube $0.398 AB Availability likely —
Desoximetasone 2.5 mg/g 71656-0087-15 Saptalis 15 tubes $0.398 AB Availability likely —
desoximetasone 2.5 mg/g 72578-0091-01 Viona 1 tube $0.398 AB Availability likely —
Desoximetasone 2.5 mg/g 51672-1270-01 Sun 1 tube $0.410 AB Availability likely +3%
Desoximetasone 2.5 mg/g 68462-0531-17 Glenmark 15 g $0.680 — FDA listed +71%
Desoximetasone 2.5 mg/g 51672-1262-01 Sun 1 tube $0.680 — FDA listed +71%
Desoximetasone 2.5 mg/g 50090-0597-00 A-S 1 tube — AB FDA listed —
Desoximetasone 2.5 mg/g 50090-5571-00 A-S 1 tube — AB FDA listed —
Desoximetasone 2.5 mg/g 63187-0646-15 Proficient 1 tube — AB FDA listed —
desoximetasone 2.5 mg/g 70771-1437-00 Zydus 1 tube — AB FDA listed —
Desoximetasone 2.5 mg/g 71205-0271-15 Proficient 1 tube — — FDA listed —
Desoximetasone 2.5 mg/g 72162-2330-02 Bryant 1 tube — AB FDA listed —
Desoximetasone 2.5 mg/g 40032-0024-60 Novel 1 tube — AB FDA listed —
desoximetasone 2.5 mg/g 63629-8641-01 Bryant 1 tube — AB FDA listed —
desoximetasone 2.5 mg/g 70771-1166-00 Zydus 1 tube — AB FDA listed —
desoximetasone 2.5 mg/g 63629-8642-01 Bryant 1 tube — AB FDA listed —
desoximetasone 2.5 mg/g 72162-1414-02 Bryant 1 tube — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2006
On the market since
Oct 2006
📍
2026
Currently FDA-listed
20 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Desoximetasone inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis Israel Pharmaceuticals Ltd
Application holderPADAGIS ISRAEL PHARMACEUTICALS LTD
FDA applicationANDA076510 (ANDA)
Labeler code45802
First marketedOct 2006
Product typeHuman Prescription Drug
Portfolio175 products on file

More NDCs from Padagis Israel Pharmaceuticals Ltd labeler code 45802

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
306
Units reimbursed last 4 qtrs
8.9K
Gross reimbursed last 4 qtrs
$6.9K
Avg / prescription
$22.61
Avg / unit
$0.7738
Latest quarter Q1 2026
49Rx
Medicaid pays / g
$0.7738
gross reimbursed
vs
NADAC / g
$0.3979
acquisition cost
=
Spread
+$0.3759
+94% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
16% FFS 84% MCO
Fee-for-service · 50 Rx Managed care · 256 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 1,740 units · 8.9 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: 2,670 units · 38.9 per 100k residents IN Ohio: no data reported OH Pennsylvania: no data reported PA New Jersey: 2,415 units · 26.0 per 100k residents NJ Massachusetts: 1,350 units · 19.3 per 100k residents MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 435 units · 7.0 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: 330 units · 6.5 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
6.538.9
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Indiana 38.9 /100k
2 New Jersey 26.0 /100k
3 Massachusetts 19.3 /100k
4 New York 8.9 /100k
5 Maryland 7.0 /100k
6 Alabama 6.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page45802-0495-35 306 Rx · $6,918
1 tube45802-0495-37 67 Rx · $2,083
Drug total (last 4 qtrs): 373 Rx · 12,960 units · $9,001 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Desoximetasone — the program that covers self-administered drugs. 6 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Desoximetasone. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$632.4K
Claims incl. refills
9K
Beneficiaries
7.4K
Spend / beneficiary
$85.57
Spend / claim
$69.95
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 45802-0493-26 · Padagis 45802-0496-14 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.